Filters

Filters

Main page content

Displaying results 1 - 10 of 44
Publication ID: PEP23-02-01-002
Published:

This Advisory outlines how healthcare providers (i.e., obstetrician-gynecologists [OB-GYNs], primary care physicians, and other professionals who treat pregnant people) can take an active role in supporting the health of pregnant individuals who have OUD and their babies.

Publication ID: PEP23-02-00-004
Published:

This document accompanies the Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants publication. It offers information about child welfare systems and what the health care provider's role is in developing a Plan of Safe Care.

Publication ID: PEP23-02-00-001
Published:

The fourth supplemental resource to SAMHSA’s Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants publication. This document contains information for pregnant people with a substance use disorder and preparing to deliver.

Publication ID: PEP23-06-05-007
Published:

This advisory discusses the epidemiology of the mental health symptoms and conditions of Long COVID, provides evidence-based resources for the treatment of those conditions, and offers possible resources.

Publication ID: PEP22-06-01-005
Published:

Community engagement is often cited as a tool to improve the health of the community and its members. This guide will review evidence related to leveraging community engagement to support the implementation and scale-up of evidence-based programs and policies.

Publication ID: PEP21-05-00-003
Published:

This brochure gives an overview of the Mental Health Parity and Addiction Equity Act of 2008. It lists some of the common limits placed on mental health and substance use disorder benefits and services.

Publication ID: PEP21-02-01-003
Published:

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

Publication ID: PEP21-02-01-002
Published:

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

Publication ID: PEP20-02-01-009
Published:

This updated workbook is a companion piece to the Anger Management Manual; it summarizes the information presented in each session of the 12-week program and provides worksheets for completing exercises.

Publication ID: PEP20-02-01-010
Published:

This updated manual contains a 12-week cognitive–behavioral anger management group treatment model. The content includes specific instructions and suggested remarks for group leaders, and exercises for group members. This model will work in a variety of clinical settings, and with diverse audiences.

Displaying 1 - 10 out of 44